Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5610713 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL28510346 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL30335844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL28520844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL6657589 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| Hydrochloric Acid SCHEMBL30833067 | 0.98 | PYGB (0.42) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520861 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520885 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL7134097 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL27920926 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4617327-A1 | POLYMERIC DYES WITH ENHANCED BIODEGRADABILITY CONTAINING SACCHARIDE OR POLYSACCHARIDE BUILDING BLOCKS | Heubach Holding Switzerland AG (Ltd) (CH) | 2025-09-17 | — | — | EP | claimed |
| CN-118668067-A | Method for recycling nickel, cobalt and manganese in waste ternary positive plate in short process | 湖南邦普循环科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-217033958-U | Test paper for detecting biological enzyme in urine | 福州汉佰康生物科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-108693149-A | A kind of device and method for measuring field rhizosphere soil original position zymogram | 中国科学院地理科学与资源研究所 | 2018-10-23 | — | — | CN | claimed |
| CN-102170994-B | Flux composition and solder paste composition | NIHON SUPERIOR CO LTD | 2014-04-30 | — | — | CN | claimed |
| CN-103338755-A | Compressed solid dosage forms | ESTEVE LABOR DR | 2013-10-02 | — | — | CN | claimed |
| CN-102170994-A | Flux composition and solder paste composition | NIHON SUPERIOR CO LTD | 2011-08-31 | — | — | CN | claimed |
| EP-4159050-B1 | STEVIOL GLYCOSIDE COMPOSITIONS FOR ORAL INGESTION OR USE | CARGILL INC (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-113321652-B | Boron removal method of moxifloxacin hydrochloride and preparation method of pure moxifloxacin hydrochloride | 山东鲁抗医药股份有限公司 | 2026-02-17 | — | — | CN | disclosed |
| EP-4637855-A1 | BIOPOLYMER SCAFFOLDS AND METHODS FOR PRODUCTION OR USE THEREOF | Bionova Medical, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250319116-A1 | Conjugated Antisense Compounds for Use in Therapy | IONIS PHARMACEUTICALS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4617327-A1 | POLYMERIC DYES WITH ENHANCED BIODEGRADABILITY CONTAINING SACCHARIDE OR POLYSACCHARIDE BUILDING BLOCKS | Heubach Holding Switzerland AG (Ltd) (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4612163-A2 | ENGINEERED VACCINIA CAPPING ENZYME VARIANTS | Codexis, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-108693149-A | A kind of device and method for measuring field rhizosphere soil original position zymogram | 中国科学院地理科学与资源研究所 | 2018-10-23 | — | — | CN | disclosed |
| CN-105194717-B | Promote the sponginum and preparation method of scalpel edge healing | 胡晨虎 | 2018-05-04 | — | — | CN | disclosed |
| CN-102170994-B | Flux composition and solder paste composition | NIHON SUPERIOR CO LTD | 2014-04-30 | — | — | CN | disclosed |
| CN-103338755-A | Compressed solid dosage forms | ESTEVE LABOR DR | 2013-10-02 | — | — | CN | disclosed |
| CN-102170994-A | Flux composition and solder paste composition | NIHON SUPERIOR CO LTD | 2011-08-31 | — | — | CN | disclosed |
| WO-1998047363-A1 | COMPOSITION FOR THE CONTROL OF CLAVICEPS AFRICANA | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1998-10-29 | — | — | WO | disclosed |
| EP-0056458-B1 | NITROSOUREA DERIVATIVES, A PROCESS FOR PREPARING SAME AND THERAPEUTIC COMPOSITIONS | Tanabe Seiyaku Co., Ltd. (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319116-A1 | Conjugated Antisense Compounds for Use in Therapy | GNE, CSGALNACT1, RNMT | PYGB 1161/4885PYGL 881/4885PYGM 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.